Esocap Featured In Fierce Pharma

“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using EsoCap’s highly promising and innovative technology.”

About Fierce Pharma
Published from New York, Fierce Pharma covers the pharma waterfront, from late-stage drug development through the entire lifecycle— tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Fierce Pharma has a broad coverage, tracking both the tiny, virtual start-ups and Big Pharma, key medical meetings and special reports that shed new light on the industry.

About EsoCap
EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach with the current standard of care. The lead candidate ESO-101 has received Orphan Drug Designation from the FDA in the treatment of EoE and is in clinical development.

EsoCap owns and develops a unique drug delivery platform, allowing the efficient topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract. With a strong IP position, EsoCap technology is widely protected.